Hypohidrotic ectodermal dysplasia — Viva

Stimulus

A school-age child has sparse fine hair, conical teeth and a history of overheating. The examiner tells you that facial appearance varies and asks you not to diagnose from the image alone.[1]

Q1: What pattern makes HED likely?

Model answer: The developmental triad is hypohidrosis or anhidrosis, hypotrichosis and hypodontia. Conical teeth, delayed eruption and heat intolerance strengthen the pattern; no single facial feature is diagnostic.[1]

Examiner probe: What is the immediate preventable harm?[1]

Answer: Heat illness. Ask about unexplained temperature elevation, hot-weather or exercise intolerance and prior confusion, collapse or seizure.[1]

Q2: Explain the genetics without saying “all HED is X-linked”

Model answer: The canonical pathway is EDA-A1 → EDAR → EDARADD → canonical NF-κB. Hemizygous EDA variants cause classic XLHED; biallelic EDAR, EDARADD or WNT10A variants can cause autosomal HED, and heterozygous EDAR/EDARADD variants can cause autosomal-dominant HED. Some WNT10A heterozygotes instead have variably penetrant milder tooth or nail findings. A phenotype-directed panel should include all four genes at minimum.[1][9]

Examiner probe: Can a heterozygous female be symptomatic?[1]

Answer: Yes. X-chromosome inactivation can produce patchy or variable sweating, dental and hair findings; “unaffected carrier” is unsafe shorthand.[1]

Q3: The child becomes confused after exercise. What do you do?

Model answer: Treat confusion after heat exposure as suspected heat stroke: call emergency services, stop exertion, move the child to a cool environment, remove excess clothing and begin active cooling immediately. Use cold-water immersion when feasible and the airway can be protected; otherwise use continuous cool-water wetting or misting with vigorous airflow. Do not delay cooling for transport. Give oral fluid only if fully alert and able to swallow safely; investigate infection separately, and do not substitute antipyretics for physical cooling.[1][8]

Examiner probe: At what ambient temperature must every child stop exercise?[1]

Answer: There is no universal cutoff. Heat, humidity, radiant exposure, exertion, clothing, illness, hydration, age and individual sweating capacity all alter risk.[1][8]

Q4: How do you confirm the diagnosis?

Model answer: Recognise the clinical pattern, draw a three-generation pedigree and arrange genetics review with phenotype-directed molecular testing. Sweat tests are supportive rather than mandatory; iodine–starch mapping can show patchy sweating. Dental examination and age-appropriate imaging define tooth development. Skin biopsy is not routine when phenotype and molecular testing are informative.[1]

Q5: Separate the two high-yield look-alikes

Model answer: Clouston syndrome is GJB6-related autosomal dominant hidrotic ectodermal dysplasia: sweating and teeth are usually preserved while nail dystrophy, alopecia and palmoplantar hyperkeratosis dominate.[2]

Model answer: IKBKG-related ectodermal dysplasia with immunodeficiency adds susceptibility to serious or unusual infection because hypomorphic NEMO variants impair NF-κB signalling. It is not uncomplicated EDA-related XLHED.[3]

Q6: Give a longitudinal plan

Model answer: Build an individual heat plan for home, school and exercise; refer early to paediatric dentistry/craniofacial care for preventive treatment and growth-adjusted prostheses; provide skin and hair care; manage nasal dryness/concretions, hearing, eye and respiratory symptoms; assess feeding, speech and psychosocial impact; and coordinate genetics counselling and transition to adult services.[1]

Q7: State the X-linked recurrence risks

Model answer: A heterozygous woman has a 50% chance of transmitting the EDA variant in each pregnancy, with sex-dependent and variable expression. An affected male transmits the variant to all daughters and no sons. Autosomal recurrence risks must be recalculated from the confirmed gene and mode rather than copied from XLHED.[1]

Q8: Is prenatal ectodysplasin replacement standard care?

Model answer: No. ER004 remains investigational and is not routine care. PMID 32250462 reports two separate intravenous trials: phase I enrolled six adults with XLHED (four male, two female) for safety, pharmacokinetics and immunogenicity; open-label phase II enrolled ten affected newborn infants with XLHED (nine male, one female) and also assessed pharmacodynamics/efficacy, finding no improvement in perspiration, thermoregulation, primary dentition, general development or sweat-gland outcomes after postnatal treatment. A later long-term report followed nine treated males: three of those postnatally treated neonates and six treated intra-amniotically from gestational week 26. The non-randomised small groups, genotype/family comparisons and conflicts limit inference.[4][6]

Examiner probe: What is the current EDELIFE design and regimen?[5][7]

Answer: As last verified in April 2025, NCT04980638 was recruiting with no posted results. It is an open-label, non-randomised, genotype-matched controlled phase 2 study with estimated enrolment 20. The protocol gives three intra-amniotic ER004 doses of 100 mg/kg estimated fetal weight, about three weeks apart from gestational week 26. A protocol is not proof of efficacy or approval.[5][7]

[1] [4] [5] [7]

References

1. [1]Wright JT, Grange DK, Fete M Hypohidrotic Ectodermal Dysplasia. GeneReviews, 1993.PMID 20301291
2. [2]Mellerio J, Greenblatt D Hidrotic Ectodermal Dysplasia 2. GeneReviews, 1993.PMID 20301379
3. [3]Döffinger R, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nature Genetics, 2001.PMID 11242109
4. [4]Schneider H, Schweikl C, Faschingbauer F, et al. A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement. International Journal of Molecular Sciences, 2023.PMID 37108325
5. [5]Schneider H, Hadj-Rabia S, Faschingbauer F, et al. Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia. Genes, 2023.PMID 36672894
6. [6]Körber I, Klein OD, Morhart P, et al. Safety and immunogenicity of Fc-EDA, a recombinant ectodysplasin A1 replacement protein, in human subjects. British Journal of Clinical Pharmacology, 2020.PMID 32250462
7. [7]Schneider H, Schneider M, Lia M, et al. Attitudes of female carriers of X-linked hypohidrotic ectodermal dysplasia towards prenatal treatment and their decisions during a pregnancy with a male fetus. Orphanet Journal of Rare Diseases, 2025.PMID 40234959
8. [8]Eifling KP, Gaudio FG, Dumke C, et al. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Heat Illness: 2024 Update. Wilderness & Environmental Medicine, 2024.PMID 38425235
9. [9]Bohring A, Stamm T, Spaich C, et al. WNT10A mutations are a frequent cause of a broad spectrum of ectodermal dysplasias with sex-biased manifestation pattern in heterozygotes. American Journal of Human Genetics, 2009.PMID 19559398